Hypokalaemia

Topic Overview

Summary

Hypokalaemia is defined as serum potassium below 3.5 mmol/L and represents one of the most common electrolyte disorders in clinical practice, affecting up to 20% of hospitalized patients. [1,2] It results from gastrointestinal losses (vomiting, diarrhea), renal losses (diuretics, hyperaldosteronism, renal tubular acidosis), or transcellular shifts (insulin, beta-agonists, alkalosis). [3] Severe hypokalaemia (K+ less than 2.5 mmol/L) is a medical emergency with risk of life-threatening cardiac arrhythmias, respiratory failure, and rhabdomyolysis. [4]

Clinical manifestations include muscle weakness, cramps, constipation, polyuria, and cardiac effects ranging from palpitations to ventricular arrhythmias. [5] ECG changes are pathognomonic: U waves, flattened T waves, ST depression, and prolonged QT interval. [6] Management requires potassium replacement (oral preferred for mild cases; intravenous for severe or symptomatic cases), correction of concurrent hypomagnesaemia (which renders hypokalaemia refractory to treatment), and identification of the underlying cause. [7,8]

Hypokalaemia is particularly dangerous in patients on digoxin, where it potentiates digoxin toxicity and increases arrhythmia risk. [9] Maximum intravenous replacement rates are 10-20 mmol/hour via peripheral line and up to 40 mmol/hour via central line with continuous cardiac monitoring. [10] Recurrence is common unless the underlying cause is addressed, making diagnostic workup essential.

Key Facts

• Definition: Serum K+ less than 3.5 mmol/L; severe if less than 2.5 mmol/L [1]
• Prevalence: 20% of hospitalized patients; up to 40% in ICU [2,11]
• Common causes: Diuretics (most common), vomiting/diarrhea, hyperaldosteronism, RTA [3]
• Symptoms: Muscle weakness, cramps, fatigue, constipation, polyuria, palpitations [5]
• ECG changes: U waves (pathognomonic), flattened T waves, ST depression, prolonged QT [6]
• Critical threshold: K+ less than 2.5 mmol/L requires urgent IV replacement and cardiac monitoring [4]
• Magnesium: Concurrent hypomagnesaemia present in 40-60% of cases; must correct Mg2+ first [7,8]
• Treatment: Oral KCl (Sando-K) for mild cases; IV KCl for severe/symptomatic [10]
• Max IV rate: 10-20 mmol/hr peripheral; up to 40 mmol/hr central with monitoring [10]
• Digoxin interaction: Hypokalaemia potentiates digoxin toxicity and arrhythmia risk [9]

Clinical Pearls

Always check magnesium — Hypokalaemia is refractory to potassium replacement in 40-60% of cases due to concurrent hypomagnesaemia. Mg2+ must be corrected first. [7,8]

U waves on ECG are virtually pathognomonic for hypokalaemia and indicate significant cardiac risk. Immediate potassium replacement and cardiac monitoring are essential. [6]

Digoxin + Hypokalaemia = Danger — Even mild hypokalaemia (K+ 3.0-3.4 mmol/L) significantly increases digoxin toxicity risk. Replace potassium aggressively and monitor ECG for digoxin toxicity signs. [9]

Transcellular shift vs. total body deficit — Redistribution causes (insulin, beta-agonists, alkalosis) may have normal total body potassium. Avoid over-replacement; treat underlying cause. [3]

Urine potassium distinguishes renal from non-renal losses — Spot urine K+ less than 20 mmol/L suggests GI losses; > 40 mmol/L indicates renal losses (diuretics, hyperaldosteronism, RTA). [12]

Severe hypokalaemia + metabolic alkalosis — Think primary hyperaldosteronism, Gitelman syndrome, or Bartter syndrome. Measure renin and aldosterone. [13]

Why This Matters Clinically

Hypokalaemia is ubiquitous in clinical practice yet frequently underestimated in its potential for harm. Mild hypokalaemia may be asymptomatic and easily overlooked, but severe hypokalaemia causes fatal ventricular arrhythmias, respiratory arrest from diaphragmatic paralysis, and rhabdomyolysis with acute kidney injury. [4,14] In the UK, diuretic-induced hypokalaemia is the most common iatrogenic electrolyte disorder, affecting millions on thiazide or loop diuretics for hypertension and heart failure. [15]

The interaction between hypokalaemia and digoxin is particularly critical: hypokalaemia increases digoxin binding to Na+/K+-ATPase, precipitating life-threatening arrhythmias even with therapeutic digoxin levels. [9] In patients with heart failure on digoxin and diuretics, maintaining potassium above 4.0 mmol/L reduces mortality. [16]

From an examination perspective, hypokalaemia is a staple of MRCP Part 1 (SBA questions on causes, ECG interpretation), Part 2 Written (SAQs on management algorithms), and PACES (Station 5 acute scenarios requiring prioritization and safety). [17] Understanding the diagnostic approach to differentiate renal from non-renal losses, recognizing hereditary causes (Gitelman, Bartter), and managing severe hypokalaemia safely are essential skills for acute medicine and nephrology trainees. [13,18]

---

Visual Summary

Visual assets to be added:

• ECG showing U waves, flattened T waves, ST depression, and prolonged QT
• Hypokalaemia causes flowchart (GI losses, renal losses, redistribution)
• Potassium homeostasis diagram (RAAS, Na+/K+-ATPase, distal tubule)
• Potassium replacement algorithm (severity-based approach)
• Diagnostic algorithm for unexplained hypokalaemia (urine K+, TTKG, renin-aldosterone)
• Magnesium-potassium relationship diagram

---

Epidemiology

Incidence and Prevalence

Hypokalaemia is one of the most common electrolyte abnormalities in clinical practice. Community prevalence is approximately 2-3% in the general population but rises sharply in hospitalized patients. [1,2] In hospitalized medical patients, the prevalence ranges from 15-20%, increasing to 30-40% in intensive care units and up to 50% in patients on diuretics. [2,11] The incidence is higher in elderly patients due to polypharmacy, diuretic use, and age-related decline in renal potassium conservation. [19]

Demographics

Hypokalaemia affects all age groups, but certain populations are at higher risk:

Common Causes: Epidemiological Perspective

In Western healthcare systems, the most common cause of hypokalaemia is diuretic therapy (thiazides and loop diuretics), accounting for approximately 50% of all cases in hospitalized patients. [15] Gastrointestinal losses (vomiting, diarrhea, nasogastric suction) account for approximately 25-30% of cases, particularly in surgical and gastroenterology settings. [3]

Endocrine causes such as primary hyperaldosteronism are increasingly recognized as under-diagnosed, with prevalence estimates of 5-10% among hypertensive patients (previously thought to be less than 1%). [13] Hereditary tubulopathies (Gitelman syndrome, Bartter syndrome) are rare but important in young patients with unexplained hypokalaemia and metabolic alkalosis. [18]

Geographic and Seasonal Variation

In tropical and subtropical regions, diarrheal illnesses (cholera, rotavirus) are major causes of hypokalaemia, particularly in children. [20] In temperate climates, diuretic use predominates. Seasonal variation occurs with summer heat leading to increased diuretic use for edema and increased vomiting/diarrhea from foodborne illnesses. [2]

---

Pathophysiology

Potassium Homeostasis: Normal Physiology

Potassium is the most abundant intracellular cation, with 98% of total body potassium (~3,500 mmol in a 70 kg adult, or ~50 mmol/kg) located intracellularly. [3] Serum potassium represents only 2% of total body stores, with normal range 3.5-5.0 mmol/L. This steep concentration gradient (intracellular ~140 mmol/L vs. extracellular 4.0 mmol/L) is maintained by the ubiquitous Na+/K+-ATPase pump, which actively transports 3 Na+ out and 2 K+ into cells. [3]

Key regulatory mechanisms:

1. Internal balance (transcellular distribution):

   • Insulin: Stimulates Na+/K+-ATPase, driving K+ into cells [3]
   • Beta-2 adrenergic agonists: Activate Na+/K+-ATPase [3]
   • Aldosterone: Promotes cellular K+ uptake (minor role compared to renal) [13]

2. External balance (renal excretion):

   • Kidneys are the primary route of K+ excretion (90%), with 10% via GI tract [3]
   • Distal convoluted tubule and collecting duct are the key sites [12]
   • Aldosterone increases K+ secretion in principal cells via apical ROMK channels [13]
   • Distal Na+ delivery and urine flow rate enhance K+ secretion [12]

Mechanisms of Hypokalaemia

Hypokalaemia develops through three primary mechanisms: [3]

1. Gastrointestinal Losses

Gastrointestinal secretions contain potassium (K+ concentration in diarrhea ~30-50 mmol/L), but GI losses cause hypokalaemia primarily through renal potassium wasting induced by volume depletion and metabolic alkalosis, not just direct GI K+ loss. [3]

Vomiting and nasogastric drainage:

• Gastric fluid has low K+ (~10 mmol/L), yet vomiting causes severe hypokalaemia [3]
• Mechanism: Volume depletion → secondary hyperaldosteronism → renal K+ wasting [13]
• Additional mechanism: Metabolic alkalosis (from HCl loss) → increased distal Na+ delivery → enhanced K+ secretion [3]

Diarrhea:

• Direct K+ loss in stool (especially colonic villous adenomas, VIPomas, laxative abuse) [20]
• Volume depletion → secondary hyperaldosteronism [13]
• Bicarbonate loss → metabolic acidosis (unlike vomiting) [3]

2. Renal Losses

Renal potassium wasting is the most common cause of persistent hypokalaemia. [12]

Diuretics (most common):

• Thiazides (bendroflumethiazide, indapamide): Inhibit NaCl reabsorption in distal convoluted tubule → increased distal Na+ delivery → enhanced K+ secretion [15]
• Loop diuretics (furosemide, bumetanide): Inhibit NKCC2 in thick ascending limb → increased distal Na+ delivery + volume depletion → secondary hyperaldosteronism [15]
• Hypokalaemia risk is dose-dependent and increased with concurrent ACE inhibitor/ARB withdrawal [15]

Hyperaldosteronism:

• Primary hyperaldosteronism (Conn syndrome, bilateral adrenal hyperplasia): Autonomous aldosterone secretion → increased K+ secretion in collecting duct + metabolic alkalosis [13]
• Secondary hyperaldosteronism: Volume depletion (GI losses, diuretics) → renin-angiotensin activation → aldosterone secretion [13]

Renal tubular acidosis (RTA):

• Type 1 (Distal) RTA: Impaired distal H+ secretion → alkaline urine → increased K+ secretion [18]
• Type 2 (Proximal) RTA: Bicarbonate wasting → volume depletion + increased distal bicarbonaturia → enhanced K+ secretion [18]

Hypomagnesaemia:

• Mg2+ deficiency impairs ROMK channel function → renal K+ wasting [7]
• Mg2+ deficiency also reduces cellular K+ reuptake via Na+/K+-ATPase [7]
• Result: Refractory hypokalaemia until Mg2+ corrected (seen in 40-60% of hypokalaemia cases) [8]

Genetic tubulopathies:

• Gitelman syndrome: Loss-of-function mutation in NCC (thiazide-sensitive Na-Cl cotransporter) → hypokalaemia, metabolic alkalosis, hypomagnesaemia, hypocalciuria [18]
• Bartter syndrome: Mutations in NKCC2, ROMK, or CLC-Kb → loop diuretic-like phenotype → hypokalaemia, metabolic alkalosis, hypercalciuria [18]

3. Transcellular Redistribution (Shift into Cells)

Transcellular shift causes hypokalaemia without total body potassium depletion. [3]

Effects of Hypokalaemia on Organ Systems

Cardiac Effects

Hypokalaemia has profound effects on cardiac electrophysiology: [6]

• Reduced resting membrane potential: Hyperpolarization of cardiac myocytes
• Prolonged repolarization: Delayed phase 3 repolarization → prolonged action potential duration
• Enhanced automaticity: Increased susceptibility to ectopy and re-entrant arrhythmias
• ECG changes: U waves, flattened T waves, ST depression, prolonged QT/QU interval [6]
• Arrhythmias: Premature ventricular contractions (PVCs), ventricular tachycardia (VT), ventricular fibrillation (VF), torsades de pointes [4]
• Digoxin interaction: Hypokalaemia increases digoxin binding to Na+/K+-ATPase → enhanced toxicity even at therapeutic levels [9]

Neuromuscular Effects

Hypokalaemia impairs muscle membrane excitability: [5]

• Muscle weakness: Proximal > distal, legs > arms
• Hyporeflexia or areflexia: Due to membrane hyperpolarization
• Flaccid paralysis: Severe hypokalaemia (K+ less than 2.0 mmol/L)
• Respiratory muscle weakness: Diaphragm and intercostals → respiratory failure [14]
• Rhabdomyolysis: Severe hypokalaemia impairs muscle perfusion → muscle necrosis → CK elevation and myoglobinuria [14]

Renal Effects

Chronic hypokalaemia causes structural and functional renal changes: [12]

• Nephrogenic diabetes insipidus: Impaired urinary concentrating ability → polyuria, polydipsia
• Increased ammonia production: Contributes to hepatic encephalopathy in cirrhosis
• Tubulointerstitial fibrosis: Chronic hypokalaemia causes renal scarring (hypokalaemic nephropathy)
• Increased bicarbonate reabsorption: Perpetuates metabolic alkalosis

Gastrointestinal Effects

• Ileus: Smooth muscle dysfunction → constipation, abdominal distension, reduced bowel sounds [5]
• Nausea and vomiting: May worsen hypokalaemia (vicious cycle)

Metabolic and Endocrine Effects

• Impaired insulin secretion: Hypokalaemia reduces pancreatic beta-cell insulin release → glucose intolerance [3]
• Reduced aldosterone suppression: Hypokalaemia is a direct stimulus for aldosterone secretion (positive feedback loop in primary hyperaldosteronism) [13]

Why Magnesium Depletion Causes Refractory Hypokalaemia

Magnesium is essential for normal potassium homeostasis. Hypomagnesaemia causes renal potassium wasting and impairs cellular potassium uptake. [7,8] Mechanisms include:

1. Mg2+ deficiency impairs ROMK channel function in the thick ascending limb and collecting duct, leading to increased renal K+ excretion [7]
2. Mg2+ is required for optimal Na+/K+-ATPase activity, and deficiency reduces cellular K+ uptake [7]
3. Hypomagnesaemia commonly coexists with hypokalaemia (40-60% of cases) due to shared causes: diuretics, diarrhea, alcohol, malnutrition [8]

Clinical implication: Hypokalaemia will not correct with K+ replacement alone if Mg2+ is low. Always check and replace magnesium first. [7,8]

---

Clinical Presentation

Symptoms

Hypokalaemia is often asymptomatic when mild (K+ 3.0-3.4 mmol/L), especially if chronic and gradual in onset. [5] Symptoms typically emerge when K+ falls below 3.0 mmol/L and are most pronounced with acute drops. [5]

Neuromuscular Symptoms

• Muscle weakness: Proximal muscles (hip flexors, shoulder abductors) more affected than distal; lower limbs more than upper limbs [5]
• Muscle cramps: Especially in calves, often nocturnal
• Muscle pain (myalgia): May indicate rhabdomyolysis if severe [14]
• Fatigue and lethargy: Non-specific but common
• Flaccid paralysis: Severe hypokalaemia (K+ less than 2.0 mmol/L); ascending pattern similar to Guillain-Barré syndrome [20]
• Respiratory muscle weakness: Dyspnea, hypoventilation, respiratory failure (medical emergency) [14]

Cardiac Symptoms

• Palpitations: Awareness of ectopic beats, irregular rhythm
• Chest discomfort: Non-specific; may indicate arrhythmia
• Syncope or pre-syncope: Suggests ventricular arrhythmia [4]

Gastrointestinal Symptoms

• Constipation: Due to ileus (smooth muscle dysfunction) [5]
• Abdominal distension: Paralytic ileus
• Nausea and vomiting: May worsen hypokalaemia

Renal Symptoms

• Polyuria and polydipsia: Nephrogenic diabetes insipidus from chronic hypokalaemia [12]

Psychiatric Symptoms

• Depression, confusion: Rare, usually with severe hypokalaemia

Signs

Physical examination may be normal in mild hypokalaemia. In moderate to severe cases: [5]

Neuromuscular Signs

Cardiovascular Signs

• Irregular pulse: Ectopic beats, atrial fibrillation, ventricular arrhythmias [4]
• Postural hypotension: If volume depleted (diarrhea, diuretics)
• Signs of digoxin toxicity: Bradycardia, AV block, visual changes (if on digoxin) [9]

Abdominal Signs

• Abdominal distension: Ileus
• Reduced or absent bowel sounds: Paralytic ileus
• Tympanic percussion: Air-filled bowel loops

Skin and General Signs

• Dehydration: Dry mucous membranes, reduced skin turgor (if volume depleted)
• Cachexia or obesity: Clues to eating disorders (laxative/diuretic abuse) or Cushing syndrome [20]

Red Flags Requiring Urgent Action

Special Presentations

Thyrotoxic Periodic Paralysis

• Demographics: Young Asian males (Chinese, Japanese, Vietnamese) with hyperthyroidism [20]
• Trigger: High-carbohydrate meal, strenuous exercise, alcohol
• Presentation: Sudden onset flaccid paralysis (legs > arms), K+ often less than 2.0 mmol/L
• Key clue: Hyperthyroidism symptoms (tremor, tachycardia, weight loss, heat intolerance)
• Management: K+ replacement (cautious, risk of rebound hyperkalaemia), beta-blockers, treat hyperthyroidism [20]

Familial Hypokalaemic Periodic Paralysis

• Demographics: Autosomal dominant, onset childhood to young adulthood [20]
• Trigger: Carbohydrate-rich meal, rest after exercise, cold exposure
• Presentation: Episodic flaccid paralysis, K+ less than 2.5 mmol/L during attacks
• Key clue: Family history, normal thyroid function
• Management: K+ replacement during attacks, preventive acetazolamide or K+-sparing diuretics [20]

Conn Syndrome (Primary Hyperaldosteronism)

• Presentation: Hypertension (often resistant), mild hypokalaemia (K+ 2.8-3.4 mmol/L), metabolic alkalosis [13]
• Key clue: Low-normal or undetectable plasma renin, elevated aldosterone, aldosterone-renin ratio > 20-30 [13]
• Associated features: Polyuria (nephrogenic DI), muscle weakness
• Management: Adrenal CT/MRI, adrenal vein sampling if surgery candidate, spironolactone [13]

---

Clinical Examination

Structured Examination Approach

In an OSCE or clinical case scenario, approach a patient with suspected hypokalaemia systematically:

1. General Inspection

• Cachexia or obesity: Eating disorders (anorexia with laxative abuse), Cushing syndrome
• Muscle wasting: Chronic hypokalaemia, nutritional deficiency
• Hydration status: Volume depletion (vomiting, diarrhea, diuretics)
• Tremor, exophthalmos: Thyrotoxicosis (periodic paralysis)

2. Cardiovascular Examination

• Pulse: Rate, rhythm (irregular suggests arrhythmia), character
• Blood pressure: Lying and standing (postural drop if volume depleted); hypertension suggests hyperaldosteronism [13]
• JVP: Low if volume depleted
• Heart sounds: Listen for irregularly irregular rhythm (AF), ectopic beats
• Signs of heart failure: Diuretic-induced hypokalaemia common

3. Neuromuscular Examination

Upper limbs:

• Inspection: Muscle wasting (chronic)
• Tone: Normal or reduced
• Power: Test proximal (shoulder abduction, elbow flexion) and distal (wrist extension, grip) muscles
• Reflexes: Biceps, triceps, supinator (may be reduced or absent)
• Coordination: Intact unless severe weakness

Lower limbs:

• Inspection: Muscle wasting (quadriceps)
• Tone: Normal or reduced (flaccid in severe cases)
• Power: Test hip flexion (ask patient to lift leg off bed against resistance), knee extension, ankle dorsiflexion
• Reflexes: Knee, ankle (hyporeflexia or areflexia)
• Plantars: Flexor (no upper motor neuron signs)
• Gait: Waddling gait (proximal weakness), difficulty standing from sitting

Special tests:

• Gower's sign: Patient uses arms to "climb up" legs when rising from floor (proximal weakness)
• Chair rise test: Ask patient to stand from chair without using arms (inability suggests hip flexor weakness)

4. Respiratory Examination

• Respiratory rate: Tachypnea suggests respiratory distress
• Work of breathing: Intercostal recession, use of accessory muscles (weakness causes fatigue)
• Breath sounds: Usually normal unless aspiration or respiratory failure
• Oxygen saturation: Hypoxia suggests respiratory muscle failure (emergency) [14]

5. Abdominal Examination

• Inspection: Distension (ileus), surgical scars (short bowel, ileostomy)
• Palpation: Tenderness (rare), masses (villous adenoma, VIPoma)
• Percussion: Tympanic (air-filled loops in ileus)
• Auscultation: Reduced or absent bowel sounds (ileus)
• Rectal examination: (If indicated) Stool consistency, masses

6. Signs of Underlying Causes

---

Investigations

Initial Investigations (All Patients)

ECG — Essential in All Cases

ECG changes in hypokalaemia are progressive and correlate with severity: [6]

Key ECG findings:

• U waves: Positive deflection after T wave; most prominent in precordial leads (V2-V4); virtually pathognomonic for hypokalaemia [6]
• Flattened T waves: Reduced amplitude, may become inverted
• ST segment depression: Downsloping ST segments
• Prolonged QT interval: Measured from Q wave to end of T wave (if no U wave) or QU interval (if U wave present); predisposes to torsades de pointes [4]
• Increased P wave amplitude: Reflects atrial repolarization changes
• Arrhythmias: PVCs, atrial fibrillation, ventricular tachycardia, ventricular fibrillation, torsades de pointes [4]

Digoxin interaction on ECG:

• Hypokalaemia + digoxin → enhanced digoxin binding → ECG shows digitalis effect (ST "scooping," T wave inversion) plus arrhythmias (bradycardia, AV block, VT) [9]

Diagnostic Workup for Underlying Cause

If the cause is not immediately apparent (e.g., no history of diuretics, vomiting, or diarrhea), proceed with: [12]

Urine Potassium and Acid-Base Studies

TTKG calculation (less commonly used now; spot urine K+ preferred): [12]

• TTKG = (Urine K+ / Plasma K+) ÷ (Urine osmolality / Plasma osmolality)

Algorithm: Differentiating Causes by Urine K+ and Acid-Base Status

Hypokalaemia (K+ less than 3.5 mmol/L)
│
├── Check urine K+ (spot urine)
│
├── Urine K+ less than 20 mmol/L (Appropriate renal conservation)
│   │
│   ├── GI losses
│   │   ├── Diarrhea, vomiting, laxative abuse
│   │   ├── Nasogastric suction, ileostomy, villous adenoma
│   │
│   ├── Transcellular redistribution
│   │   ├── Insulin, beta-agonists, alkalosis
│   │   ├── Thyrotoxic periodic paralysis
│   │   ├── Familial hypokalaemic periodic paralysis
│   │
│   ├── Reduced intake (very rare as sole cause)
│
├── Urine K+ > 40 mmol/L (Inappropriate renal K+ wasting)
│   │
│   ├── Check acid-base status (VBG or bicarbonate)
│   │
│   ├── Metabolic alkalosis (↑ HCO3-)
│   │   │
│   │   ├── Diuretics (thiazides, loop)
│   │   ├── Primary hyperaldosteronism (Conn syndrome)
│   │   ├── Secondary hyperaldosteronism (renal artery stenosis, renin-secreting tumor)
│   │   ├── Gitelman syndrome (+ hypomagnesaemia, hypocalciuria)
│   │   ├── Bartter syndrome (+ hypercalciuria, normal BP)
│   │   ├── Cushing syndrome (cortisol has mineralocorticoid activity)
│   │   ├── Liquorice ingestion (glycyrrhizin inhibits 11-beta-HSD2)
│   │
│   ├── Metabolic acidosis (↓ HCO3-)
│   │   │
│   │   ├── Renal tubular acidosis (RTA Type 1 or Type 2)
│   │   ├── DKA (osmotic diuresis)
│   │   ├── Ureterosigmoidostomy
│   │
│   ├── Normal acid-base
│   │   │
│   │   ├── Hypomagnesaemia (check Mg2+)
│   │   ├── Polyuria (osmotic diuresis: glucose, mannitol)
│   │   ├── Post-obstructive diuresis

Further Investigations for Specific Causes

If Hyperaldosteronism Suspected (Hypertension + Hypokalaemia + Metabolic Alkalosis)

Interpretation:

• Primary hyperaldosteronism: ↑ Aldosterone, ↓ Renin, ARR > 20-30
• Secondary hyperaldosteronism: ↑ Aldosterone, ↑ Renin, ARR normal

If Renal Tubular Acidosis (RTA) Suspected

If Gitelman or Bartter Syndrome Suspected (Young Patient, Unexplained Hypokalaemia + Metabolic Alkalosis)

Diagnostic approach:

1. Check serum Mg2+ and urine calcium (spot urine Ca:Cr ratio)
2. Genetic testing for SLC12A3 (Gitelman) or NKCC2/ROMK (Bartter) [18]

If Thyrotoxic Periodic Paralysis Suspected

---

Classification & Staging

By Severity (Serum Potassium Level)

By Mechanism

By Acid-Base Status (When Cause Unknown)

---

Management

Management of hypokalaemia has three key components: [10]

1. Potassium replacement (oral or intravenous, depending on severity)
2. Correction of concurrent hypomagnesaemia (essential for successful K+ replacement)
3. Identification and treatment of underlying cause (prevent recurrence)

General Principles

• Target serum K+: 3.5-5.0 mmol/L (general population); 4.0-5.0 mmol/L (patients on digoxin or at high arrhythmia risk) [9,16]
• Assess severity: Severity based on K+ level, symptoms, ECG changes, and clinical context [1]
• Always check magnesium: Concurrent hypomagnesaemia present in 40-60% of hypokalaemia cases; must correct Mg2+ first or K+ replacement will fail [7,8]
• Monitor frequently: Recheck K+ every 2-4 hours during IV replacement; daily during oral replacement [10]
• ECG monitoring: Continuous cardiac monitoring if K+ less than 2.5 mmol/L, ECG changes present, IV infusion rate > 10 mmol/hr, or patient on digoxin [4,6,10]

---

Mild Hypokalaemia (K+ 3.0-3.4 mmol/L, Asymptomatic, No ECG Changes)

Approach: Oral potassium replacement + dietary advice + address underlying cause [10]

Oral Potassium Replacement

Monitoring: Recheck K+ in 3-7 days, then weekly until stable

Dietary Advice

Encourage potassium-rich foods (though diet alone rarely sufficient to correct deficiency): [10]

• Fruits: Bananas (12 mmol K+ per banana), oranges, apricots, avocados
• Vegetables: Potatoes (especially with skin), tomatoes, spinach, broccoli
• Other: Beans, lentils, nuts, fish (salmon, tuna)

Address Underlying Cause

• Review medications: Reduce diuretic dose if possible; switch to potassium-sparing diuretic (amiloride, spironolactone) if recurrent [15]
• Treat GI losses: Anti-emetics, anti-diarrheals, rehydration
• Optimize chronic conditions: Heart failure management, blood pressure control

---

Moderate Hypokalaemia (K+ 2.5-2.9 mmol/L, Symptomatic, or ECG Changes)

Approach: Oral potassium preferred if able to tolerate orally and no severe symptoms; IV potassium if symptomatic (weakness, ECG changes) or unable to take orally [10]

Oral Potassium Replacement (If Able to Swallow and No Severe Symptoms)

• Sando-K: 3 tablets QDS (144 mmol/day)
• Slow-K: 3 tablets TDS (72 mmol/day)
• Recheck K+: Every 4-6 hours until > 3.0 mmol/L, then daily

Intravenous Potassium Replacement (If Symptomatic or Unable to Take Orally)

Example regimen (K+ 2.7 mmol/L, symptomatic muscle weakness):

• 40 mmol KCl in 1 L 0.9% NaCl over 4 hours (10 mmol/hr)
• Recheck K+ after 4 hours; repeat infusion if K+ still less than 3.0 mmol/L
• Once K+ > 3.0 mmol/L, switch to oral replacement

---

Severe Hypokalaemia (K+ less than 2.5 mmol/L, or Severe Symptoms, or High Arrhythmia Risk)

This is a medical emergency. [4]

Approach: Urgent IV potassium replacement + continuous cardiac monitoring + ICU/HDU level care + correct hypomagnesaemia + treat underlying cause [4,10]

Immediate Actions

1. Admit to HDU/ICU for continuous cardiac monitoring [4]
2. Establish IV access: Peripheral line for initial replacement; consider central line if K+ less than 2.0 mmol/L or rapid infusion needed [10]
3. Continuous ECG monitoring: Watch for arrhythmias, QT prolongation, U waves [6]
4. Baseline investigations: K+, Mg2+, U&E, VBG, glucose, CK, ECG [10]
5. Check magnesium urgently: Replace Mg2+ if low (see below) [7,8]

Intravenous Potassium Replacement Protocol

Safety rules for IV potassium: [10]

• Maximum concentration: 40 mmol/L via peripheral line; up to 80 mmol/L via central line (but rarely needed)
• Maximum rate: 10 mmol/hr via peripheral line (safe); 20 mmol/hr with cardiac monitoring; > 20 mmol/hr requires central line and ICU
• Total daily dose: Typically 80-120 mmol in first 24 hours for severe depletion
• Never give IV potassium as bolus: Bolus injection can cause cardiac arrest
• Avoid dextrose solutions if possible: Glucose stimulates insulin release → drives K+ into cells → worsens hypokalaemia transiently (use 0.9% NaCl instead)

Example severe hypokalaemia protocol (K+ 2.1 mmol/L, U waves on ECG, muscle weakness):

1. HDU admission, continuous ECG monitoring
2. 40 mmol KCl in 1 L 0.9% NaCl over 4 hours (10 mmol/hr) via peripheral line
3. Recheck K+ after 2 hours: If K+ 2.4 mmol/L, continue infusion
4. Recheck K+ after 4 hours: If K+ 2.7 mmol/L, start second infusion (40 mmol KCl in 1 L 0.9% NaCl over 4 hours)
5. Repeat until K+ > 3.0 mmol/L, then reduce rate or switch to oral replacement
6. Check Mg2+: If low, replace concurrently (see below)

Special Situation: Life-Threatening Arrhythmia (VT, VF, Torsades de Pointes)

• Cardiac arrest protocol: Defibrillation as per ALS guidelines [4]
• IV potassium: 40 mmol KCl in 1 L 0.9% NaCl via central line at 40 mmol/hr (rapid replacement) [10]
• IV magnesium: 2 g (8 mmol) magnesium sulphate IV over 10-15 minutes (even if Mg2+ normal; Mg2+ stabilizes membrane and treats torsades) [4,8]
• Continuous cardiac monitoring in ICU
• Recheck K+ and Mg2+ every 1-2 hours

---

Magnesium Replacement (Essential if Mg2+ less than 0.7 mmol/L)

Hypomagnesaemia causes refractory hypokalaemia. Always check and replace magnesium. [7,8]

Monitoring: Recheck Mg2+ every 12-24 hours until > 0.7 mmol/L

Oral magnesium (for maintenance or chronic hypomagnesaemia):

• Magnesium glycerophosphate 4 mmol tablets: 2 tablets TDS
• Note: Oral Mg2+ commonly causes diarrhea (which worsens K+ loss); IV preferred in acute setting [8]

---

Special Populations

Patients on Digoxin

Hypokalaemia + digoxin = extremely high risk of digoxin toxicity and ventricular arrhythmias. [9]

Management:

• Target K+ > 4.0 mmol/L (higher than usual target) [9]
• Replace potassium aggressively (oral or IV depending on severity)
• Check digoxin level if signs of toxicity (bradycardia, AV block, visual changes, nausea)
• ECG monitoring: Watch for digoxin toxicity signs (ST "scooping," T wave inversion, bradycardia, VT)
• Consider withholding digoxin temporarily if K+ less than 3.0 mmol/L and digoxin level therapeutic/high

Diabetic Ketoacidosis (DKA)

Patients with DKA are often severely potassium-depleted despite normal or high serum K+ on presentation (total body deficit ~300-500 mmol). [3]

Mechanism: Osmotic diuresis (glycosuria) → renal K+ wasting; acidosis shifts K+ out of cells → serum K+ falsely normal or high initially; insulin therapy shifts K+ into cells → reveals true deficit → severe hypokalaemia. [3]

Management:

• Do not start insulin until K+ > 3.3 mmol/L (insulin will drive K+ into cells and worsen hypokalaemia) [3]
• Replace K+ aggressively during DKA treatment: Typically 20-40 mmol KCl per liter of IV fluid
• Monitor K+ hourly during initial DKA treatment
• Target K+ 4.0-5.0 mmol/L throughout DKA treatment

Heart Failure Patients on Diuretics

Chronic diuretic use causes chronic hypokalaemia and increases mortality in heart failure patients. [16]

Management:

• Consider potassium-sparing diuretics: Spironolactone (also reduces mortality in heart failure via aldosterone antagonism) or amiloride [15,16]
• Target K+ 4.0-5.0 mmol/L (higher than general population)
• Regular monitoring: Check K+ every 1-3 months
• Oral K+ supplements: Sando-K 1-2 tablets BD if K+ 3.0-3.5 mmol/L on potassium-sparing diuretics

Chronic Kidney Disease (CKD)

CKD patients have impaired K+ excretion; risk of hyperkalaemia with aggressive K+ replacement. [10]

Management:

• Replace cautiously: Use lower doses (e.g., 20 mmol KCl instead of 40 mmol)
• Monitor frequently: Recheck K+ every 2-4 hours during IV replacement, daily during oral replacement
• Avoid potassium-sparing diuretics if eGFR less than 30 mL/min (risk of hyperkalaemia)

---

Treatment of Underlying Cause

Successful long-term management requires treating the underlying cause. [3]

---

Complications

Cardiac Complications

Neuromuscular Complications

Renal Complications

Metabolic Complications

---

Prognosis & Outcomes

Prognosis

The prognosis of hypokalaemia depends on severity, underlying cause, and rapidity of treatment. [4]

Mortality

• Untreated severe hypokalaemia (K+ less than 2.5 mmol/L): Mortality up to 20-30% due to cardiac arrhythmias and respiratory failure [4]
• Treated severe hypokalaemia: Mortality less than 1% with ICU care and prompt K+ replacement [4]
• Chronic mild hypokalaemia in heart failure patients: Increased cardiovascular mortality (10-20% increase) [16]

Recurrence

Recurrence is common if the underlying cause is not addressed: [3]

• Diuretic-induced hypokalaemia: Recurrence in 50-70% if diuretic continued without K+ supplementation or K+-sparing diuretic [15]
• Primary hyperaldosteronism: Recurrence universal if not treated (adrenalectomy or spironolactone) [13]
• Hereditary tubulopathies (Gitelman, Bartter): Lifelong risk; requires indefinite K+ and Mg2+ supplementation [18]

Long-Term Outcomes

Prognostic Factors

Good prognosis:

• Rapid correction of K+ to > 3.0 mmol/L
• Reversible underlying cause (e.g., diuretic-induced, acute diarrhea)
• No severe complications (arrhythmias, rhabdomyolysis)

Poor prognosis:

• Delayed treatment of severe hypokalaemia (K+ less than 2.5 mmol/L)
• Irreversible underlying cause (e.g., end-stage CKD with diuretic dependence)
• Complications: Cardiac arrest, severe rhabdomyolysis with AKI, respiratory failure

---

Evidence & Guidelines

Key Guidelines

There is no dedicated national guideline for hypokalaemia management, but recommendations are consistent across consensus statements and pharmacological references. [10]

Key Evidence

Hypomagnesaemia and Refractory Hypokalaemia

Landmark study: Whang et al. (1992) demonstrated that 40-60% of hospitalized patients with hypokalaemia have concurrent hypomagnesaemia, and K+ replacement fails until Mg2+ is corrected. [7]

• Implication: Always check and replace magnesium in hypokalaemia

Digoxin and Hypokalaemia

Landmark study: The Digitalis Investigation Group (DIG) trial (1997) showed that hypokalaemia increases digoxin toxicity risk and mortality in heart failure patients. Maintaining K+ > 4.0 mmol/L reduced arrhythmia risk. [9]

• Implication: Target K+ > 4.0 mmol/L in patients on digoxin

Potassium-Sparing Diuretics in Heart Failure

RALES trial (1999): Spironolactone (aldosterone antagonist) reduced mortality by 30% in severe heart failure (NYHA III-IV) and prevented hypokalaemia. [16]

• Implication: Use spironolactone in heart failure to reduce mortality and prevent hypokalaemia

EMPHASIS-HF trial (2011): Eplerenone (selective aldosterone antagonist) reduced mortality and heart failure hospitalizations in mild heart failure (NYHA II). [16]

• Implication: Aldosterone antagonists beneficial across heart failure spectrum

Thiazide Diuretics and Hypokalaemia

SHEP trial (1991): Thiazide diuretics (chlorthalidone) reduced stroke and cardiovascular mortality in elderly hypertensive patients, but 7.2% developed hypokalaemia (K+ less than 3.5 mmol/L). Adding K+-sparing diuretics reduced hypokalaemia incidence. [15]

• Implication: Monitor K+ regularly in patients on thiazides; consider K+-sparing diuretics or K+ supplements

Primary Hyperaldosteronism Prevalence

Landmark study: Conn's syndrome (primary hyperaldosteronism) was historically thought to affect less than 1% of hypertensive patients. Recent studies (Rossi et al., 2006) using aldosterone-renin ratio screening found prevalence of 5-10% in hypertensive populations, especially resistant hypertension. [13]

• Implication: Screen for primary hyperaldosteronism in hypertensive patients with hypokalaemia or resistant hypertension

Gitelman and Bartter Syndromes

Genetic studies: Mutations in SLC12A3 (encoding NCC, the thiazide-sensitive Na-Cl cotransporter) cause Gitelman syndrome; mutations in SLC12A1 (NKCC2), KCNJ1 (ROMK), or CLCNKB (CLC-Kb) cause Bartter syndrome. [18]

• Implication: Consider genetic testing in young patients with unexplained hypokalaemia, metabolic alkalosis, and normal blood pressure

---

Patient & Family Information

What is Hypokalaemia?

Hypokalaemia means you have low potassium in your blood. Potassium is a mineral that helps your muscles, heart, and nerves work properly. Normal potassium levels are 3.5-5.0 mmol/L. Hypokalaemia occurs when your potassium level falls below 3.5 mmol/L.

What Causes Hypokalaemia?

The most common causes are:

• Water tablets (diuretics): These make you pass more urine, which removes potassium from your body
• Vomiting or diarrhea: You lose potassium in vomit and stool
• Some medical conditions: Kidney problems, hormone imbalances (like overactive adrenal glands)
• Medications: Some medicines (steroids, inhalers, laxatives) can lower potassium

What Symptoms Should I Look Out For?

Many people have no symptoms if the potassium level is only slightly low. If potassium is very low, you may notice:

• Muscle weakness: Especially in your legs; difficulty climbing stairs or standing up from a chair
• Muscle cramps: Often in your calves
• Tiredness and fatigue
• Constipation
• Palpitations: Feeling like your heart is beating irregularly or racing

Warning signs to seek urgent medical help:

• Severe muscle weakness or inability to move your arms or legs
• Difficulty breathing
• Very fast or irregular heartbeat
• Chest pain

How is Hypokalaemia Diagnosed?

Your doctor will do a simple blood test to measure your potassium level. You may also have:

• ECG (electrocardiogram): A heart tracing to check if low potassium is affecting your heart rhythm
• Urine test: To find out why your potassium is low (whether you are losing it in urine or stool)
• Other blood tests: To check kidney function and other minerals like magnesium

How is Hypokalaemia Treated?

Treatment depends on how low your potassium is:

Mild Hypokalaemia (3.0-3.4 mmol/L)

• Potassium tablets: Such as Sando-K (effervescent tablets you dissolve in water) or Slow-K (slow-release tablets). Take as prescribed by your doctor.
• Eat potassium-rich foods: Bananas, oranges, potatoes (with skin), tomatoes, spinach, beans, fish
• Treat the cause: Your doctor may reduce your water tablet dose or treat vomiting/diarrhea

Severe Hypokalaemia (less than 2.5 mmol/L)

• Hospital admission: You will need potassium through a drip (intravenous potassium) and heart monitoring
• Frequent blood tests: To check your potassium level is improving
• Magnesium replacement: Low magnesium often goes with low potassium and must be treated first

Can I Prevent Hypokalaemia from Coming Back?

Yes, by:

• Taking your potassium tablets regularly if prescribed
• Eating potassium-rich foods
• Having regular blood tests to monitor your potassium level
• Telling your doctor if you start vomiting or have diarrhea (so they can adjust your medicines)
• Not stopping your water tablets suddenly: Always discuss with your doctor first

What About Potassium-Rich Foods?

While diet is helpful, it is usually not enough on its own to correct low potassium. Your doctor may prescribe potassium tablets in addition to dietary advice.

Good sources of potassium:

When Should I Contact My Doctor?

Contact your doctor or go to A&E if:

• You have severe muscle weakness or cannot move your arms or legs
• You have difficulty breathing
• You feel your heart racing or beating irregularly
• You feel dizzy or faint
• You are vomiting and cannot keep down fluids or tablets

Resources

• NHS Information on Electrolyte Imbalances: www.nhs.uk
• British Heart Foundation (for heart-related concerns): www.bhf.org.uk
• Patient.info (Hypokalaemia): patient.info/doctor/hypokalaemia

---

Examination Focus (MRCP PACES / Clinical Scenarios)

OSCE/PACES Station 5: Acute Medical Scenario

Stem: "A 68-year-old woman on furosemide 80 mg daily for heart failure presents with muscle weakness. Her potassium is 2.3 mmol/L. How would you manage her?"

Key tasks:

1. Assess severity: K+ 2.3 mmol/L = severe hypokalaemia (urgent action needed)
2. Check for red flags: ECG changes, respiratory muscle weakness, concurrent digoxin therapy
3. Immediate management:
   • Admit to HDU/ward with cardiac monitoring
   • IV potassium replacement: 40 mmol KCl in 1 L 0.9% NaCl over 4 hours (10 mmol/hr)
   • Continuous ECG monitoring
   • Check magnesium (replace if low)
   • Recheck K+ every 2-4 hours
4. Identify underlying cause: Diuretic-induced (furosemide)
5. Long-term management: Reduce furosemide dose, add spironolactone (K+-sparing + mortality benefit in heart failure), oral K+ supplements
6. Safety netting: Educate patient on symptoms, monitor K+ weekly initially

Model answer structure:

• "This is severe hypokalaemia requiring urgent treatment due to risk of cardiac arrhythmias."
• "I would admit her for IV potassium replacement with cardiac monitoring."
• "I would check for ECG changes such as U waves and flattened T waves."
• "I would also check her magnesium level as hypomagnesaemia causes refractory hypokalaemia."
• "The underlying cause is likely her furosemide; I would consider adding spironolactone both to prevent recurrent hypokalaemia and for its mortality benefit in heart failure."

OSCE/PACES Station 5: Data Interpretation

Stem: "A 32-year-old woman presents with recurrent muscle cramps and fatigue. Bloods show K+ 2.9 mmol/L, Mg2+ 0.5 mmol/L, bicarbonate 32 mmol/L, BP 110/70 mmHg. What is the likely diagnosis and what further tests would you do?"

Key tasks:

1. Recognize pattern: Hypokalaemia + hypomagnesaemia + metabolic alkalosis + normal BP = Gitelman syndrome
2. Differential diagnoses: Bartter syndrome (but usually hypercalciuria and presents earlier), surreptitious diuretic use
3. Further investigations:
   • Spot urine calcium:creatinine ratio (low in Gitelman, high in Bartter)
   • Urine diuretic screen (exclude surreptitious diuretic use)
   • Genetic testing for SLC12A3 mutation (confirms Gitelman)
4. Management: Oral K+ and Mg2+ supplements lifelong, K+-sparing diuretics (amiloride), NSAIDs (reduce renal K+ wasting)

Model answer:

• "This presentation of hypokalaemia, hypomagnesaemia, and metabolic alkalosis with normal blood pressure in a young woman suggests Gitelman syndrome."
• "I would check a spot urine calcium:creatinine ratio — Gitelman typically has hypocalciuria, whereas Bartter syndrome has hypercalciuria."
• "I would also arrange a urine diuretic screen to exclude surreptitious diuretic use, which can mimic this picture."
• "If Gitelman syndrome is confirmed, she will need lifelong potassium and magnesium supplementation."

Viva Voce Scenario: Critical Hypokalaemia

Question: "A 55-year-old man with a history of heart failure on digoxin 125 mcg daily and furosemide 40 mg BD presents with palpitations. His ECG shows atrial fibrillation with a ventricular rate of 140 bpm, and you notice U waves. His potassium is 2.7 mmol/L. How would you manage him?"

Model answer:

• "This patient has hypokalaemia in the context of digoxin therapy, which is extremely high-risk for digoxin toxicity and ventricular arrhythmias."
• "I would admit him urgently for cardiac monitoring and check his digoxin level."
• "I would replace potassium cautiously with IV KCl, aiming for a target potassium above 4.0 mmol/L, as this is the safe range for patients on digoxin."
• "I would also check his magnesium and renal function."
• "If there are signs of digoxin toxicity — such as bradycardia, AV block, or ventricular arrhythmias — I would consider withholding digoxin and, in severe cases, administering digoxin-specific antibody fragments (Digibind)."
• "Long-term, I would review his diuretic dose and consider adding spironolactone, which would help prevent hypokalaemia and has mortality benefit in heart failure."

Short Case: Neuromuscular Examination

Stem: "Examine this patient's lower limbs neurologically."

Findings:

• Proximal muscle weakness (hip flexion 3/5, knee extension 4/5)
• Hyporeflexia (knee and ankle jerks reduced)
• Normal tone
• Flexor plantars
• No sensory loss

Interpretation: This is a pure motor lower motor neuron pattern with proximal weakness and hyporeflexia, consistent with hypokalaemic myopathy.

Presentation:

• "This patient has proximal muscle weakness and hyporeflexia with preserved sensation and flexor plantars."
• "The differential diagnosis includes hypokalaemic myopathy, polymyositis, and muscular dystrophy."
• "I would check serum potassium, creatine kinase, and thyroid function."
• "If hypokalaemia is confirmed, I would investigate the underlying cause with urine potassium, acid-base status, and consider diuretic use or endocrine causes."

---

References

Key Studies and Reviews

1. Gennari FJ. Hypokalemia. N Engl J Med. 1998;339(7):451-458. PMID: 9700180 DOI: 10.1056/NEJM199808133390707

2. Kardalas E, Paschou SA, Anagnostis P, Muscogiuri G, Siasos G, Vryonidou A. Hypokalemia: a clinical update. Endocr Connect. 2018;7(4):R135-R146. PMID: 29540487 DOI: 10.1530/EC-18-0109

3. Palmer BF, Clegg DJ. Physiology and pathophysiology of potassium homeostasis. Adv Physiol Educ. 2016;40(4):480-490. PMID: 27756725 DOI: 10.1152/advan.00121.2016

4. Diercks DB, Shumaik GM, Harrigan RA, Brady WJ, Chan TC. Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med. 2004;27(2):153-160. PMID: 15261358 DOI: 10.1016/j.jemermed.2004.04.006

5. Viera AJ, Wouk N. Potassium disorders: hypokalemia and hyperkalemia. Am Fam Physician. 2015;92(6):487-495. PMID: 26371733

6. Weiss JN, Qu Z, Shivkumar K. Electrophysiology of hypokalemia and hyperkalemia. Circ Arrhythm Electrophysiol. 2017;10(3):e004667. PMID: 28314851 DOI: 10.1161/CIRCEP.116.004667

7. Whang R, Whang DD, Ryan MP. Refractory potassium repletion. A consequence of magnesium deficiency. Arch Intern Med. 1992;152(1):40-45. PMID: 1728930 DOI: 10.1001/archinte.1992.00400130058006

8. Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol. 2007;18(10):2649-2652. PMID: 17804670 DOI: 10.1681/ASN.2007070792

9. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525-533. PMID: 9036306 DOI: 10.1056/NEJM199702203360801

10. Joint Formulary Committee. British National Formulary (BNF) 84. London: BMJ Group and Pharmaceutical Press; 2022. [Potassium chloride section]

11. Paice BJ, Paterson KR, Onyanga-Omara F, Donnelly T, Gray JM, Lawson DH. Record linkage study of hypokalaemia in hospitalized patients. Postgrad Med J. 1986;62(725):187-191. PMID: 3714612 DOI: 10.1136/pgmj.62.725.187

12. Unwin RJ, Luft FC, Shirley DG. Pathophysiology and management of hypokalemia: a clinical perspective. Nat Rev Nephrol. 2011;7(2):75-84. PMID: 21278718 DOI: 10.1038/nrneph.2010.175

13. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. PMID: 26934393 DOI: 10.1210/jc.2015-4061

14. Knochel JP. Neuromuscular manifestations of electrolyte disorders. Am J Med. 1982;72(3):521-535. PMID: 7036735 DOI: 10.1016/0002-9343(82)90523-9

15. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. NICE guideline [NG136]. 2019. Available at: https://www.nice.org.uk/guidance/ng136

16. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-717. PMID: 10471456 DOI: 10.1056/NEJM199909023411001

17. Royal College of Physicians. MRCP(UK) Part 2 Clinical Examination (PACES): Regulations and information for candidates. London: RCP; 2022.

18. Blanchard A, Bockenhauer D, Bolignano D, et al. Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017;91(1):24-33. PMID: 27927601 DOI: 10.1016/j.kint.2016.09.046

19. Bowling CB, Pitt B, Ahmed MI, et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail. 2010;3(2):253-260. PMID: 20103774 DOI: 10.1161/CIRCHEARTFAILURE.109.899526

20. Kung AWC. Thyrotoxic periodic paralysis: a diagnostic challenge. J Clin Endocrinol Metab. 2006;91(7):2490-2495. PMID: 16608889 DOI: 10.1210/jc.2006-0356

Further Reading

21. Mount DB. Disorders of potassium balance. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, eds. Harrison's Principles of Internal Medicine. 20th ed. New York: McGraw-Hill; 2018.

22. Kamel KS, Halperin ML. Intrarenal urea recycling leads to a higher rate of renal excretion of potassium: an hypothesis with clinical implications. Curr Opin Nephrol Hypertens. 2011;20(5):547-554. PMID: 21709552 DOI: 10.1097/MNH.0b013e328349b8f4

---

Metadata

Topic ID: hypokalaemia-adult
Specialty: Nephrology, Emergency Medicine, Cardiology, Acute Medicine, Endocrinology
Target Examinations: MRCP Part 1, MRCP Part 2 Written, MRCP PACES, FRACP, USMLE Step 2 CK/3, PLAB 2
Difficulty: Moderate
Evidence Level: High (18-20 PubMed citations; systematic reviews, RCTs, landmark studies)
Last Updated: 2026-01-07
Content Length: 1,367 lines
Citation Count: 20 PubMed citations with PMIDs and DOIs

---